Keratins are proteins that help skin cells maintain their structural integrity and withstand mechanical stress. However, recent research shows that their functions extend beyond structural support: keratins also regulate signaling pathways involved in stress responses and immunity.
KRT16 as a Therapeutic Target in Inflammatory Skin Diseases
Researchers at the University of Michigan (USA) investigated the role of keratin K16 in skin diseases.
Under normal conditions, K16 is barely expressed in the epidermis, except in the skin of the palms and soles. However, its expression rapidly increases in response to skin injury and inflammation. In addition, mutations in the KRT16 gene cause pachyonychia congenita – an incurable disorder characterized by painful calluses on the palms and soles, cysts, and nail dystrophy.
Analysis of skin cells from patients with psoriasis and hidradenitis showed that high KRT16 expression was associated with reduced activity of genes induced by interferon (IFN) responses. In contrast, affected skin from patients with mutations in KRT16 and KRT6A and pachyonychia congenita, as well as skin from KRT16-deficient mice, showed increased activity of IFN-response genes. At the same time, levels of the OAS1/3 and ISG15 proteins, which are associated with type I interferon responses, were markedly elevated.
The researchers also found that K16 interacts with RIG-I and MDA5 – receptors that recognize viral RNA and initiate interferon production. These findings point to a role for K16 in regulating IFN signaling in inflammatory skin diseases.
K16 Restrains the Inflammatory Response in the Skin
The researchers conducted experiments in K16-deficient mice. Following treatment with imiquimod, a compound that induces psoriasiform skin inflammation, these mice developed a stronger inflammatory response, with greater epidermal thickening, impaired differentiation, and increased keratinocyte proliferation. Repeatedly stressed skin areas showed increased neutrophil infiltration. In addition, expression of OAS1 – an IFN-responsive gene – was increased in the upper layers of the epidermis. These findings indicate that K16 restrains the skin’s inflammatory response to stress and psoriasiform disease.
Experiments in human keratinocytes helped clarify a possible mechanism underlying this effect. K16 prevented 14-3-3ε from interacting with RIG-I, a receptor that initiates the IFN response. In cells lacking KRT16, the IFN response to poly(I:C) – a synthetic double-stranded RNA analog – was markedly enhanced, whereas restoration of normal K16 expression suppressed this response.
Topical Ruxolitinib Reduces Skin Lesions in K16-Deficient Mice
In the next experiment, the researchers applied ruxolitinib – a JAK inhibitor that blocks IFN signaling – to the affected skin of KRT16-deficient mice. Within one week, the thickness of the affected skin decreased by 25%, accompanied by reduced OAS1 protein levels.
These findings show that keratins not only provide structural support to skin cells but also regulate their responses to stress and innate immunity. The results improve our understanding of the mechanisms underlying inflammatory skin diseases and may help develop new treatments for pachyonychia congenita.
KRT16 as a Therapeutic Target in Skin Cancer
In some epithelial tumors, including cutaneous squamous cell carcinoma, KRT16 activity is increased. In this disease, high KRT16 expression is associated with a poor prognosis, whereas type I IFN signaling promotes antitumor immunity.
Suppression of KRT16 reduced tumor cell migration and invasion, prevented cancer cells from acquiring stem-like properties, and reduced lung metastasis formation in mice by 60–80%. Conversely, increased KRT16 expression enhanced these processes.
Because K16 suppresses the IFN response, reducing its activity may enhance antitumor immunity in tumors with high KRT16 expression. Therefore, the KRT16-IFN signaling pathway may represent a therapeutic target in a range of diseases. The effects of targeting this pathway depend on the disease context.
Reference
- A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing β5-integrin/c-met signaling pathway
- Keratin 16 spatially inhibits type I interferon responses in stressed and diseased skin
- Keratin 16 puts the brakes on type I interferon signalling